TWI BIOTECHNOLOGY, INC.

Otros idiomas TWi Biotechnology, Inc.

Acciones

6610

TW0006610009

Precio de cierre Taipei Exchange Otros sitios de cotización 00:00:00 14/06/2024			Varia. Cinco días.	Varia. 1 de enero.
13 ^TWD	+0,39 %		-1,52 %	-7,14 %

09/04	TWi Biotechnology, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
2023	TWi Biotechnology, Inc. informa de los resultados del semestre finalizado el 30 de junio de 2023	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/04
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23
TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)	02/06/23
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	15/08/21
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203	07/01/21
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	12/08/20
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA	07/05/20
Twi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	09/04/19
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy	15/11/18
TWi Biotechnology, Inc. Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	20/10/18
TWi Biotechnology, Inc. Announces Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	26/02/18
TWi Biotechnology Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment	27/06/16
TWi Biotechnology, Inc. Enters Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals	22/12/15
TWi Biotechnology, Inc. Completes Multinational Phase II Dose-Ranging Study of AC-201	06/08/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Asegure y Aumente el Rendimiento de sus Inversiones con nuestro Equipo de Expertos a su lado

Asegurar mis Inversiones

fermer